PAREXEL and Meiji Pharmaceutical University (MPU) announced a new Joint Program for Clinical Research and Clinical Trial Management for undergraduate students. The academic program will offer MPU students an accredited, four-week course designed to prepare them for careers in the biopharmaceutical industry.
Designed to meet the growing demands of biopharmaceutical companies conducting clinical research both inside and outside of Japan, the collaborative program combines PAREXEL’s global clinical research expertise with MPU’s established pharmaceutical training experience. All classes will be conducted in English from PAREXEL Academy lecturers and are consistent with current global clinical trial standards and practices. Following a series of two-week pilot programs, the first official program will be offered in November 2019. In addition, select MPU students may be eligible for enrollment at the PAREXEL Academy in Berlin in the future.
“Pharmaceutical research and development expenditures in Japan have nearly doubled since 20001. With the number of Japanese students going overseas for education on the decline, this creates an opportunity for the younger generation to play an active role in clinical research,” said Shogo Nakamori, Corporate Vice President, Asia-Pacific and General Manager, PAREXEL Japan. “This program will leverage PAREXEL’s expertise and MPU’s strong educational foundation to ensure students receive the necessary training to succeed in the global pharmaceutical industry of the future.”
For more than a decade, the PAREXEL Academy has designed and implemented a variety of learning programs in clinical research for students in Asia, Europe, and the United States. PAREXEL’s collaboration with MPU is the company’s second academic program in Japan, following PAREXEL’s first program with Kyoto Pharmaceutical University which launched in early 2016. Since PAREXEL Academy’s inception, approximately 5,000 students have graduated from its programs.